Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2007

View Archived Issues

Recent Merck and AstraZeneca patents report new therapeutic agents for metabolic disorders

Recent patents cover therapeutic agents for inflammatory disorders

Two phase I studies of PTC-124 in healthy adults completed

FdCyd and THU studied for treatment of solid tumors

Novel camptothecin conjugate with promising efficacy and pharmacokinetic profile

Replacement of regular insulin with Oral-lyn studied in adults, adolescents

Certolizumab pegol inhibits cytokine production by monocytes

Preclinical profile of MORAb-009 reported by Morphotek

Vaccine targeting prostatic acid phosphatase tested in prostate cancer patients

Promising preclinical profile of STI-1698, a topoisomerase I inhibitor developed at Sigma-Tau

LX-1031 begins phase Ib study for IBS

Introgen initiates efficacy analyses of Advexin phase III study

NS-2359 begins second phase II study for depression

U.S. development of CollaRx Gentamicin Surgical Implant to open at phase III

Agensys discover AGS-16 as a novel target for the treatment of kidney cancer

Exelixis cleared to resume clinical testing of XL-999

Dosing completed in phase I metastatic melanoma study of Provecta

Novartis in-licenses CYT002-NicQb for treatment of nicotine addiction

New data confirm oral bioavailability of AL-309

PCK-3145 shows evidence of clinical activity in metastatic prostate cancer patients

Miraxion fails to meet endpoints in phase III Huntington's studies

Phase IIa results for i.v. cannabinor in postoperative pain

EpiCeram comparable to Cutivate in treating atopic dermatitis symptoms

Alitretinoin shows retreatment benefit in chronic hand eczema

Abbott discontinues development of levosimendan in U.S.

Singulair approved to prevent exercise-induced bronchoconstriction

Novel therapeutic agents for atherosclerosis reported in recent Merck and Merck Frosst patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Sun Pharma to acquire Merck spinoff Organon for $11.75B
BioWorld
Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...